Aaron Hanyu-Deutmeyer, DO
Pain Medicine · New Orleans, LANPI 1932586617
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,750 of the $16,527 with a category attached, or 71.1%. It is spread thinly across 30 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $4,298 and has fallen 73.5% since, to $1,138 in 2025.
Across 217 payments — averaging $76.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$4K
- Medtronic$3K
- Boston Scientific$2K
- Abbott$2K
- Relievant Medsystems, Inc.$1K
- SPR Therapeutics, Inc$870
- plus $5K from 24 others
What the payments were for
- Consulting fees$1951%
- Travel & lodging$4,58228%
- Food & beverage$11,75071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 52 | $3,527 |
| Medtronic(2 entities) | 29 | $2,657 |
| Boston Scientific | 24 | $1,908 |
| Abbott | 20 | $1,842 |
| Relievant Medsystems, Inc. | 10 | $1,166 |
| SPR Therapeutics, Inc | 13 | $870 |
| Pacira Pharmaceuticals Incorporated | 4 | $609 |
| Avanos Medical | 7 | $591 |
| Ipsen Biopharmaceuticals, Inc | 12 | $437 |
| AbbVie(2 entities) | 5 | $407 |
| Stimwave Technologies Incorporated | 3 | $396 |
| Stryker | 4 | $330 |
| Nalu Medical, Inc. | 4 | $314 |
| Averitas Pharma Inc. | 3 | $255 |
| MML US, Inc. | 3 | $248 |
| Saluda Medical Americas, Inc. | 2 | $217 |
| Wenzel Spine, Inc. | 1 | $154 |
| Interventional Pain Technologies Inc. | 1 | $134 |
| Globus Medical | 3 | $77 |
| Amgen | 2 | $70 |
| Johnson & Johnson | 1 | $63 |
| Biohaven Pharmaceuticals, Inc. | 2 | $54 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $38 |
| GRT US Holding, Inc. | 3 | $31 |
| Novartis | 1 | $21 |
| Vertex | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Electronic Waveform Lab, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,871
- Senza Spinal Cord Stimulation System$1,886
- INTELLIS$848
- PROCLAIM$732
- SPRINT PNS System$535
- Iovera$493
- Zilretta$493
- CFNS StimQ Peripheral Nerve StimulatorSystem$390
- SCS FreedonSpinal Cord Stimulator$390
- WaveWriter Alpha Prime 16$386
- Senza$386
- SYNCHROMEDII$382
- BOTOX$339
- ETERNA$310
- Nalu Neurostimulation System$279
- INTELLIS ADAPTIVESTIM$261
- Qutenza$247
- Proclaim Family of SCS IPGs$222
- SPINEJACK$219
- Omnia$218
How this compares
$16,527 in reported general payments places this provider in the 85th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $10,242 |
| Buprenorphine | 26 | $9,922 |
| BelbucaBuprenorphine Hcl | 12 | $7,855 |
| SavellaMilnacipran Hcl | 13 | $5,968 |
| Gabapentin | 264 | $4,477 |
| Celecoxib | 160 | $3,502 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 250 | $2,925 |
| Pregabalin | 143 | $2,823 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 124 | $2,755 |
| Methocarbamol | 135 | $1,762 |
| Tizanidine Hcl | 128 | $1,613 |
| Duloxetine Hcl | 69 | $1,476 |
| Diclofenac Sodium | 31 | $919 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 11 | $589 |
| Baclofen | 43 | $581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $41 | $7,85512 claims |
| AbbVieSavella | $407 | $5,96813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 97 pain medicine providers in Louisiana.
Other pain medicine in New Orleans
- Alan KayeNew Orleans$76K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Yashar EshraghiNew Orleans$22K
- Trevor JohnsonNew Orleans$11K
- Eric RoysterNew Orleans$10K
- Lesley WalshNew Orleans$10K
- Alvah WickboldtNew Orleans$7K
- Arya BekhradiNew Orleans$6K
- Reda TolbaNew Orleans$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.